Induction and maintenance alpha-interferon therapy in myelofibrosis with myeloid metaplasia

G. Barosi, L. N. Liberato, A. Costa, A. Buratti, F. Di Dio, S. Salvatore, E. Ascari

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

In 12 patients having myelofibrosis with myeloid metaplasia (MMM), recombinant-α interferon (r-αINF) was given for 16 weeks at an initial dose of 3 x 106 U/day as a cytoreductive agent. At the end of the 16th wk, Hb showed minor changes; WBC were reduced from 43 x 109/l, range 6.4-69.4, to 16 x 109/l, range 5-39 (p = 0.05); platelets decreased from 845 x 109/l, range 215-1748, to 370 x 109/l, range 96-730 (p = 0.005). 2 cases responded at the starting dose, while the effective dose was 5 x 106 U/d in the others. Minor changes in spleen size were noted, while no significant changes in bone marrow fibrosis occurred. After induction therapy, 3 patients were allocated to maintenance therapy (from 10 up to 34 months). To maintain platelet count lower than 500 x 109/l, the required r-α-INF dose was constantly 10 MU/wk, while the same result was not achieved in 1 case with hydroxyurea, 1 g/die. The association with hydroxyurea, 500 mg/die, allowed reduction of the r-αINF dose to 6 MU/die in 1 other case.

Original languageEnglish
Pages (from-to)12-14
Number of pages3
JournalEuropean Journal of Haematology, Supplement
Volume45
Issue number52
Publication statusPublished - 1990

Fingerprint

Primary Myelofibrosis
Hydroxyurea
Interferon-alpha
Interferons
Maintenance
Platelet Count
Blood Platelets
Spleen
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Induction and maintenance alpha-interferon therapy in myelofibrosis with myeloid metaplasia. / Barosi, G.; Liberato, L. N.; Costa, A.; Buratti, A.; Di Dio, F.; Salvatore, S.; Ascari, E.

In: European Journal of Haematology, Supplement, Vol. 45, No. 52, 1990, p. 12-14.

Research output: Contribution to journalArticle

Barosi, G. ; Liberato, L. N. ; Costa, A. ; Buratti, A. ; Di Dio, F. ; Salvatore, S. ; Ascari, E. / Induction and maintenance alpha-interferon therapy in myelofibrosis with myeloid metaplasia. In: European Journal of Haematology, Supplement. 1990 ; Vol. 45, No. 52. pp. 12-14.
@article{2825eded74054502aa56c02a2bd8b204,
title = "Induction and maintenance alpha-interferon therapy in myelofibrosis with myeloid metaplasia",
abstract = "In 12 patients having myelofibrosis with myeloid metaplasia (MMM), recombinant-α interferon (r-αINF) was given for 16 weeks at an initial dose of 3 x 106 U/day as a cytoreductive agent. At the end of the 16th wk, Hb showed minor changes; WBC were reduced from 43 x 109/l, range 6.4-69.4, to 16 x 109/l, range 5-39 (p = 0.05); platelets decreased from 845 x 109/l, range 215-1748, to 370 x 109/l, range 96-730 (p = 0.005). 2 cases responded at the starting dose, while the effective dose was 5 x 106 U/d in the others. Minor changes in spleen size were noted, while no significant changes in bone marrow fibrosis occurred. After induction therapy, 3 patients were allocated to maintenance therapy (from 10 up to 34 months). To maintain platelet count lower than 500 x 109/l, the required r-α-INF dose was constantly 10 MU/wk, while the same result was not achieved in 1 case with hydroxyurea, 1 g/die. The association with hydroxyurea, 500 mg/die, allowed reduction of the r-αINF dose to 6 MU/die in 1 other case.",
author = "G. Barosi and Liberato, {L. N.} and A. Costa and A. Buratti and {Di Dio}, F. and S. Salvatore and E. Ascari",
year = "1990",
language = "English",
volume = "45",
pages = "12--14",
journal = "Scandinavian journal of haematology. Supplementum",
issn = "0902-4506",
publisher = "Wiley-Blackwell",
number = "52",

}

TY - JOUR

T1 - Induction and maintenance alpha-interferon therapy in myelofibrosis with myeloid metaplasia

AU - Barosi, G.

AU - Liberato, L. N.

AU - Costa, A.

AU - Buratti, A.

AU - Di Dio, F.

AU - Salvatore, S.

AU - Ascari, E.

PY - 1990

Y1 - 1990

N2 - In 12 patients having myelofibrosis with myeloid metaplasia (MMM), recombinant-α interferon (r-αINF) was given for 16 weeks at an initial dose of 3 x 106 U/day as a cytoreductive agent. At the end of the 16th wk, Hb showed minor changes; WBC were reduced from 43 x 109/l, range 6.4-69.4, to 16 x 109/l, range 5-39 (p = 0.05); platelets decreased from 845 x 109/l, range 215-1748, to 370 x 109/l, range 96-730 (p = 0.005). 2 cases responded at the starting dose, while the effective dose was 5 x 106 U/d in the others. Minor changes in spleen size were noted, while no significant changes in bone marrow fibrosis occurred. After induction therapy, 3 patients were allocated to maintenance therapy (from 10 up to 34 months). To maintain platelet count lower than 500 x 109/l, the required r-α-INF dose was constantly 10 MU/wk, while the same result was not achieved in 1 case with hydroxyurea, 1 g/die. The association with hydroxyurea, 500 mg/die, allowed reduction of the r-αINF dose to 6 MU/die in 1 other case.

AB - In 12 patients having myelofibrosis with myeloid metaplasia (MMM), recombinant-α interferon (r-αINF) was given for 16 weeks at an initial dose of 3 x 106 U/day as a cytoreductive agent. At the end of the 16th wk, Hb showed minor changes; WBC were reduced from 43 x 109/l, range 6.4-69.4, to 16 x 109/l, range 5-39 (p = 0.05); platelets decreased from 845 x 109/l, range 215-1748, to 370 x 109/l, range 96-730 (p = 0.005). 2 cases responded at the starting dose, while the effective dose was 5 x 106 U/d in the others. Minor changes in spleen size were noted, while no significant changes in bone marrow fibrosis occurred. After induction therapy, 3 patients were allocated to maintenance therapy (from 10 up to 34 months). To maintain platelet count lower than 500 x 109/l, the required r-α-INF dose was constantly 10 MU/wk, while the same result was not achieved in 1 case with hydroxyurea, 1 g/die. The association with hydroxyurea, 500 mg/die, allowed reduction of the r-αINF dose to 6 MU/die in 1 other case.

UR - http://www.scopus.com/inward/record.url?scp=0025036649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025036649&partnerID=8YFLogxK

M3 - Article

C2 - 2279538

AN - SCOPUS:0025036649

VL - 45

SP - 12

EP - 14

JO - Scandinavian journal of haematology. Supplementum

JF - Scandinavian journal of haematology. Supplementum

SN - 0902-4506

IS - 52

ER -